Maternal RSV vaccination to protect infants: current evidence and future directions

Abstract

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) burden among infants. Maternal vaccination is a promising preventive strategy, conferring passive immunity through transplacental antibody transfer. The current narrative review was conducted to summarize the current evidence of efficacy and safety of maternal RSV vaccination and assess the practical barriers to its implementation. This review was based on a structured literature search of PubMed/MEDLINE and Google Scholar to identify peer-reviewed studies published between January 2022 and March 2025 using terms such as “maternal RSV vaccine”, “efficacy”, “safety”, “pregnancy”, “Abrysvo”, and “hesitancy”. The review included 5 clinical trials evaluating maternal RSV vaccines and 17 observational and survey studies assessing vaccine acceptance across diverse settings. The bivalent RSVpreF vaccine (Abrysvo) is the only licensed maternal RSV vaccine as of May 2025. In the MATISSE phase 3 trial (n=7,358), the vaccine demonstrated 81.8% efficacy against medically attended RSV-LRTI at 90 days and 69.4% at 180 days, with 57.1% efficacy against severe RSV-LRTI. No major safety concerns were identified; adverse events and preterm birth rates were comparable between groups. In contrast, trials of GSK’s RSVPreF3-Mat vaccine revealed higher rates of preterm birth (6.8% vs. 4.9%) and a numerical imbalance in infant deaths (0.4% vs. 0.2%), prompting early termination. Across 17 studies (n=14,959), RSV vaccine acceptance ranged from 39% (France) to 87% (Netherlands), with safety concerns and cultural context influencing attitudes. This review highlights that maternal RSV vaccination with RSVpreF offers effective infant protection with an acceptable safety profile. Future research should focus on long-term infant outcomes, comparative effectiveness in diverse settings, and next-generation vaccines. Implementation will require public trust, cultural sensitivity, and equitable global access.

Keywords

Vaccination / pregnancy / immunization / newborn / infant / attitudes

References

[1] Du Y, Yan R, Wu X, Zhang X, Chen C, Jiang D, et al. Global burden and trends of respiratory syncytial virus infection across different age groups from 1990 to 2019: A systematic analysis of the Global Burden of Disease 2019 Study. Int J Infect Dis. 2023; 135: 70-6.

[2] Driscoll AJ, Arshad SH, Bont L, Brunwasser SM, Cherian T, Englund JA, et al. Does respiratory syncytial virus lower respiratory illness in early life cause recurrent wheeze of early childhood and asthma? Critical review of the evidence and guidance for future studies from a World Health Organization-sponsored meeting. Vaccine. 2020; 38: 2435-48.

[3] Zar HJ, Cacho F, Kootbodien T, Mejias A, Ortiz JR, Stein RT, et al. Early-life respiratory syncytial virus disease and long-term respiratory health. Lancet Respir Med. 2024; 12: 810-21.

[4] Munro APS, Martinón-Torres F, Drysdale SB, Faust SN. The disease burden of respiratory syncytial virus in Infants. Curr Opin Infect Dis. 2023; 36: 379-84.

[5] Lade C, Bayer L, Huebbe B, Riedel J, Melnik S, Brestrich G, et al. Clinical and economic inpatient burden of respiratory syncytial virus (RSV) infections in children < 2 years of age in Germany, 2014-2019: a retrospective health claims analysis. Infection. 2025; 53: 393-404.

[6] Haeberer M, López-Ibáñez de Aldecoa A, Seabroke S, Ramirez Agudelo JL, Mora L, Sarabia L, et al. Economic burden of children hospitalized with respiratory syncytial virus infection in Spain, 2016-2019. Vaccine. 2025; 43: 126512.

[7] Drysdale SB, Broadbent L. Respiratory syncytial virus (RSV): over 60 years of research but still so many unanswered questions. Ther Adv Infect Dis. 2023; 10: 20499361231159991.

[8] World Health Organization. Respiratory syncytial virus (RSV) [Internet]. WHO; c2025 [cited 2025 Apr 9]. Available from: https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv)

[9] Obando-Pacheco P, Justicia-Grande AJ, Rivero-Calle I, Rodríguez-Tenreiro C, Sly P, Ramilo O, et al. Respiratory Syncytial Virus Seasonality: A Global Overview. J Infect Dis. 2018; 217: 1356-64.

[10] Staadegaard L, Caini S, Wangchuk S, Thapa B, de Almeida WAF, de Carvalho FC, et al. Defining the seasonality of respiratory syncytial virus around the world: National and subnational surveillance data from 12 countries. Influenza Other Respir Viruses. 2021; 15: 732-41.

[11] Chadha M, Hirve S, Bancej C, Barr I, Baumeister E, Caetano B, et al. ; WHO RSV Surveillance Group. Human respiratory syncytial virus and influenza seasonality patterns-Early findings from the WHO global respiratory syncytial virus surveillance. Influenza Other Respir Viruses. 2020; 14: 638-46.

[12] Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. ; Respiratory Virus Global Epidemiology Network; Nair H; RESCEU investigators. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022; 399: 2047-64.

[13] Havdal LB, Bøås H, Bekkevold T, Bakken Kran AM, Rojahn AE, Størdal K, et al. Risk factors associated with severe disease in respiratory syncytial virus infected children under 5 years of age. Front Pediatr. 2022; 10: 1004739.

[14] Cai W, Buda S, Schuler E, Hirve S, Zhang W, Haas W. Risk factors for hospitalized respiratory syncytial virus disease and its severe outcomes. Influenza Other Respir Viruses. 2020; 14: 658-70.

[15] Wang X, Li Y, Shi T, Bont LJ, Chu HY, Zar HJ, et al. ; Respiratory Virus Global Epidemiology Network; RESCEU investigators. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data. Lancet. 2024; 403: 1241-53.

[16] Tenenbaum T, Liese J, Welte T, Rademacher J. Respiratory Syncytial Virus-Associated Respiratory Diseases in Children and Adults. Dtsch Arztebl Int. 2024; 121: 303-12.

[17] Borchers AT, Chang C, Gershwin ME, Gershwin LJ. Respiratory syncytial virus-a comprehensive review. Clin Rev Allergy Immunol. 2013; 45: 331-79.

[18] Bont L, Versteegh J, Swelsen WT, Heijnen CJ, Kavelaars A, Brus F, et al. Natural reinfection with respiratory syncytial virus does not boost virus-specific T-cell immunity. Pediatr Res. 2002; 52: 363-7.

[19] Nduaguba SO, Tran PT, Choi Y, Winterstein AG. Respiratory syncytial virus reinfections among infants and young children in the United States, 2011-2019. PLoS One. 2023; 18: e0281555.

[20] Foley DA, Minney-Smith CA, Lee WH, Oakes DB, Hazelton B, Ford TJ, et al. Respiratory Syncytial Virus Reinfections in Children in Western Australia. Viruses. 2023; 15: 2417.

[21] Fitzpatrick T, Buchan SA, Mahant S, Fu L, Kwong JC, Stukel TA, et al. Pediatric Respiratory Syncytial Virus Hospitalizations, 2017-2023. JAMA Netw Open. 2024; 7: e2416077.

[22] Lastrucci V, Pacifici M, Puglia M, Alderotti G, Berti E, Del Riccio M, et al. Seasonality and severity of respiratory syncytial virus during the COVID-19 pandemic: a dynamic cohort study. Int J Infect Dis. 2024; 148: 107231.

[23] Young M, Smitherman L. Socioeconomic Impact of RSV Hospitalization. Infect Dis Ther. 2021; 10: 35-45.

[24] MacNeil A, McMorrow M. RSV burden and prevention in children in LMICs. Lancet Glob Health. 2024; 12: e1563-4.

[25] Li X, Willem L, Antillon M, Bilcke J, Jit M, Beutels P. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Med. 2020; 18: 82.

[26] Domachowske JB. New and Emerging Passive Immunization Strategies for the Prevention of RSV Infection During Infancy. J Pediatric Infect Dis Soc. 2024; 13: S115-24.

[27] Magnapera A, Riccio A, Curcio A, Tramontozzi C, Piermatteo L, D’Anna S, et al. Insights into the Currently Available Drugs and Investigational Compounds Against RSV with a Focus on Their Drug-Resistance Profiles. Viruses. 2025; 17: 793.

[28] Mejías A, Ramilo O. Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants. Biologics. 2008; 2: 433-9.

[29] Jones JM, Fleming-Dutra KE, Prill MM, Roper LE, Brooks O, Sánchez PJ, et al. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023; 72: 920-5.

[30] Madhi SA, Simões EAF, Acevedo A, Novoa Pizarro JM, Shepard JS, Railkar RA, et al. A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025; 231: e478-87.

[31] Thambi N, Phuah JY, Staupe RP, Tobias LM, Cao Y, McKelvey T, et al. Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150. J Infect Dis. 2025; 231: e488-96.

[32] Sinha A, Railkar RA, Castagnini L, Guerra A, Likos A, Lutkiewicz J, et al. Evaluation of a monoclonal antibody against respiratory syncytial virus, Clesrovimab, in infants and children: Comprehensive rationale and study design for the late-stage clinical trials. Contemp Clin Trials. 2025;[pub ahead of print].

[33] Anderer S. FDA Approves New RSV Monoclonal Antibody to Protect Infants. JAMA. 2025;[Epub ahead of print].

[34] Gatt D, Martin I, AlFouzan R, Moraes TJ. Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). Pathogens. 2023; 12: 154.

[35] Saso A, Kampmann B. Maternal Immunization: Nature Meets Nurture. Front Microbiol. 2020; 11: 1499.

[36] Cinicola B, Conti MG, Terrin G, Sgrulletti M, Elfeky R, Carsetti R, et al. The Protective Role of Maternal Immunization in Early Life. Front Pediatr. 2021; 9: 638871.

[37] Papazisis G, Topalidou X. Maternal Vaccination for the Prevention of Infantile RSV Disease: An Overview of the Authorized, In-Progress, and Rejected Vaccine Candidates. Vaccines (Basel). 2024; 12: 980.

[38] FDA Approves First Vaccine for Pregnant Individuals to Prevent RSV in Infants [Internet]. [Cited 2025 Apr 9]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-vaccine-pregnant-individuals-prevent-rsv-infants

[39] Che Y, Gribenko AV, Song X, Handke LD, Efferen KS, Tompkins K, et al. Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine. Sci Transl Med. 2023; 15: eade6422.

[40] Abrysvo: respiratory syncytial virus vaccine (bivalent, recombinant) [Internet]. European Medicines Agency; c1995- 2025 [cited 2025 Apr 9]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/abrysvo

[41] Willemsen JE, Borghans JAM, Bont LJ, Drylewicz J. Disagreement FDA and EMA on RSV Maternal Vaccination: Possible Consequence for Global Mortality. Pediatr Infect Dis J. 2024; 43: e1-2.

[42] Dieussaert I, Hyung Kim J, Luik S, Seidl C, Pu W, Stegmann JU, et al. RSV Prefusion F Protein-Based Maternal Vaccine - Preterm Birth and Other Outcomes. N Engl J Med. 2024; 390: 1009-21.

[43] Li Q, Li H, Li Z, Wang Y. Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue. MedComm (2020). 2024; 5: e70016.

[44] Álvarez Aldean J, Rivero Calle I, Rodríguez Fernández R, Aceituno Mata S, Bellmunt A, Prades M, et al. Cost-effectiveness Analysis of Maternal Immunization with RSVpreF Vaccine for the Prevention of Respiratory Syncytial Virus Among Infants in Spain. Infect Dis Ther. 2024; 13: 1315-31.

[45] Hutton DW, Prosser LA, Rose AM, Mercon K, Ortega-Sanchez IR, Leidner AJ, et al. Cost-Effectiveness of Maternal Vaccination to Prevent Respiratory Syncytial Virus Illness. Pediatrics. 2024; 154: e2024066481.

[46] McCormack S, Thompson C, Nolan M, Imcha M, Dee A, Saunders J, et al. Maternal awareness, acceptability and willingness towards respiratory syncytial virus (RSV) vaccination during pregnancy in Ireland. Immun Inflamm Dis. 2024; 12: e1257.

[47] Sallam M, Kherfan T, Al-Farajat A, Nemrawi L, Atawneh N, Fram R, et al. Attitude to RSV Vaccination Among a Cohort of Pregnant Women in Jordan: A Cross-Sectional Survey Study. Health Sci Rep. 2025; 8: e70319.

[48] Kherfan T, Sallam M. Prospective Attitudes towards Respiratory Syncytial Virus (RSV) Vaccination: Validation of a Survey Instrument among Young Females in Jordan Pending Vaccine Authorization. Vaccines (Basel). 2023; 11: 1386.

[49] Sallam M, Snygg J, Allam D, Kassem R. From Protection to Prevention: Redefining Vaccines in the Context of Antimicrobial Resistance. Cureus. 2024; 16: e60551.

[50] Razai MS, Mansour R, Ravindran P, Freeman S, Mason-Apps C, Morris J, et al. Facilitators and barriers to vaccination uptake in pregnancy: A qualitative systematic review. PLoS One. 2024; 19: e0298407.

[51] Sallam M, Al-Mahzoum K, Yousef ZM, Alfouzan JS, Alharbi MJ, Alsubaiei MK, et al. Perceived benefits, information, vaccination history, and conspiracy beliefs as significant determinants of RSV vaccine acceptance among Arab seniors. Ther Adv Vaccines Immunother. 2025; 13: 25151355251324384.

[52] Khan T, Malik S, Rafeekh L, Halder S, Desai S, Das Bhattacharya S. Facilitators and barriers to maternal immunization and strategies to improve uptake in low-income and lower-middle income countries: A systematic review. Hum Vaccin Immunother. 2024; 20: 2411823.

[53] Giles ML, Mason E, Muñoz FM, Moran AC, Lambach P, Merten S, et al. Antenatal care service delivery and factors affecting effective tetanus vaccine coverage in low- and middle-income countries: Results of the Maternal Immunisation and Antenatal Care Situational analysis (MIACSA) project. Vaccine. 2020; 38: 5278-85.

[54] Gavaruzzi T, Ceccarelli A, Nanni C, Vignali C, Colonnello V, Caserotti M, et al. Knowledge and Attitudes Regarding Respiratory Syncytial Virus (RSV) Prevention: A Systematic Review. Vaccines (Basel). 2025; 13: 159.

[55] Kelleher K, Subramaniam N, Drysdale SB. The recent landscape of RSV vaccine research. Ther Adv Vaccines Immunother. 2025; 13: 25151355241310601.

[56] Principi N, Perrone S, Esposito S. Challenges and Limitations of Current RSV Prevention Strategies in Infants and Young Children: A Narrative Review. Vaccines. 2025; 13: 717.

[57] Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019; 4: 5.

[58] Martín-Martín A, Thelwall M, Orduna-Malea E, Delgado López-Cózar E. Google Scholar, Microsoft Academic, Scopus, Dimensions, Web of Science, and OpenCitations’ COCI: a multidisciplinary comparison of coverage via citations. Scientometrics. 2021; 126: 871-906.

[59] Kampmann B, Madhi SA, Munjal I, Simões EAF, Pahud BA, Llapur C, et al. ; MATISSE Study Group. Bivalent Prefusion F Vaccine in Pregnancy to Prevent RSV Illness in Infants. N Engl J Med. 2023; 388: 1451-64.

[60] Simões EAF, Center KJ, Tita ATN, Swanson KA, Radley D, Houghton J, et al. Prefusion F Protein-Based Respiratory Syncytial Virus Immunization in Pregnancy. N Engl J Med. 2022; 386: 1615-26.

[61] Madhi SA, Polack FP, Piedra PA, Munoz FM, Trenholme AA, Simões EAF, et al. ; Prepare Study Group. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. N Engl J Med. 2020; 383: 426-39.

[62] Banooni P, Gonik B, Epalza C, Reyes O, Madhi SA, Gomez-Go GD, et al. Efficacy, immunogenicity, and safety of an investigational maternal respiratory syncytial virus prefusion F protein-based vaccine. Clin Infect Dis. 2025:ciaf033.

[63] Holland C, Baker M, Bates A, Hughes C, Richmond PC, Carlson S, et al. Parental awareness and attitudes towards prevention of respiratory syncytial virus in infants and young children in Australia. Acta Paediatr. 2024; 113: 786-94.

[64] McClymont E, Wong JMH, Forward L, Blitz S, Barrett J, Bogler T, et al. ; COVERED Team. Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada. Vaccine. 2025; 50: 126818.

[65] Cubizolles C, Barjat T, Chauleur C, Bruel S, Botelho-Nevers E, Gagneux-Brunon A. Evaluation of intentions to get vaccinated against influenza, COVID 19, pertussis and to get a future vaccine against respiratory syncytial virus in pregnant women. Vaccine. 2023; 41: 7342-7.

[66] Damatopoulou A, Matalliotakis M, Diamanta Y, Pikrides I, Ierapetritis E, Kakouri P, et al. Prospective Attitudes Towards Respiratory Syncytial Virus (RSV) Vaccine in Pregnant Women in Greece. Behav Med. 2025; 51: 1-6.

[67] Miraglia Del Giudice G, Sansone V, Airoma F, Angelillo S, Licata F, Di Giuseppe G. Respiratory Syncytial Virus: Willingness towards a Future Vaccine among Pregnant Women in Italy. Vaccines (Basel). 2023; 11: 1691.

[68] Wang Q, Yang L, Li L, Xiu S, Yang M, Wang X, et al. Investigating parental perceptions of respiratory syncytial virus (RSV) and attitudes to RSV vaccine in Jiangsu, China: Insights from a cross-section study. Vaccine. 2025; 44: 126570.

[69] Limaye RJ, Fesshaye B, Singh P, Karron RA. RSV awareness, risk perception, causes, and terms: Perspectives of pregnant and lactating women in Kenya to inform demand generation efforts for maternal RSV vaccines. Hum Vaccin Immunother. 2023; 19: 2258580.

[70] Adhikari S, Chapagain RH, Maharjan J, Kunwar K, Pudasaini S, Singh P, et al. Acceptance of New Respiratory Syncytial Virus Vaccine among Pregnant Women in Nepal for Future Routine Immunization: A Descriptive Crosssectional Study. JNMA J Nepal Med Assoc. 2024; 62: 372-7.

[71] Harteveld LM, van Leeuwen LM, Euser SM, Smit LJ, Vollebregt KC, Bogaert D, et al. Respiratory syncytial virus (RSV) prevention: Perception and willingness of expectant parents in the Netherlands. Vaccine. 2025; 44: 126541.

[72] Paulson S, Munro APS, Cathie K, Bedford H, Jones CE. Protecting Against Respiratory Syncytial Virus: An Online Questionnaire Study Exploring UK Parents' Acceptability of Vaccination in Pregnancy or Monoclonal Antibody Administration for Infants. Pediatr Infect Dis J. 2025; 44: S158-61.

[73] Beusterien KM, Law AW, Maculaitis MC, Will O, Kopenhafer L, Olsen P, et al. Healthcare Providers’ and Pregnant People’s Preferences for a Preventive to Protect Infants from Serious Illness Due to Respiratory Syncytial Virus. Vaccines (Basel). 2024; 12: 560.

[74] DeSilva MB, Vazquez-Benitez G, Seburg EM, Henderson MSG, Ehresmann K, Zibley LJ, et al. Pregnant persons perceptions and uptake of prenatal RSV vaccine - Minnesota, 2023-2024. Vaccine. 2025; 54: 126958.

[75] Kuntz JL, Babu TM, Feldstein LR, Englund JA, Frivold CJ, Groom HC, et al. Knowledge About Respiratory Syncytial Virus and Acceptance of Infant Monoclonal Antibody for RSV and RSV Vaccination During Pregnancy. Pediatr Infect Dis J. 2025; 44: S162-6.

[76] Saper JK, Heffernan M, Simon NE, Davis MM, Macy ML. RSV Vaccination Intention Among People Who Are or Plan to Become Pregnant. Pediatrics. 2024; 153: e2023065140.

[77] Tucker T, Garvey Z, O’Sullivan D, Loza A. Acceptance of the Respiratory Syncytial Virus Vaccine in Pregnant Individuals. O&G Open. 2024; 1: 026.

[78] Scarpaci M, Bracaloni S, Esposito E, De Angelis L, Baglivo F, Casini B, et al. ; RSVComNet Italia. RSV Disease Burden in Primary Care in Italy: A Multi-Region Pediatric Study, Winter Season 2022-2023. Influenza Other Respir Viruses. 2024; 18: e13282.

[79] Ciapponi A, Palermo MC, Sandoval MM, Baumeister E, Ruvinsky S, Ulloa-Gutierrez R, et al. Respiratory syncytial virus disease burden in children and adults from Latin America: a systematic review and meta-analysis. Front Public Health. 2024; 12: 1377968.

[80] Brüssow H. Respiratory syncytial virus: health burden, disease prevention, and treatment-recent progress and lessons learned. Microlife. 2025; 6: uqaf003.

[81] Baraldi E, Checcucci Lisi G, Costantino C, Heinrichs JH, Manzoni P, Riccò M, et al. RSV disease in infants and young children: Can we see a brighter future? Hum Vaccin Immunother. 2022; 18: 2079322.

[82] McLellan JS. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol. 2015; 11: 70-5.

[83] Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, et al. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med. 2015; 7: 309ra162.

[84] Anastassopoulou C, Medić S, Ferous S, Boufidou F, Tsakris A. Development, Current Status, and Remaining Challenges for Respiratory Syncytial Virus Vaccines. Vaccines (Basel). 2025; 13: 97.

[85] Graham BS. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev. 2011; 239: 149-66.

[86] Riccò M, Abu-Raya B, Icardi G, Spoulou V, Greenberg D, Pecurariu OF, et al. Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options. Vaccines (Basel). 2024; 12: 1317.

[87] Duan Y, Liu Z, Zang N, Cong B, Shi Y, Xu L, et al. Landscape of respiratory syncytial virus. Chin Med J (Engl). 2024; 137: 2953-78.

[88] Silva GSD, Borges SG, Pozzebon BB, Souza APD. Immune Responses to Respiratory Syncytial Virus Vaccines: Advances and Challenges. Microorganisms. 2024; 12: 2305.

[89] Phijffer EW, de Bruin O, Ahmadizar F, Bont LJ, Van der Maas NA, Sturkenboom MC, et al. Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes. Cochrane Database Syst Rev. 2024; 5: CD015134.

[90] Baumgartner MK, Hanslik G, Schneider M, Franitza M, Schneider M, Rieger H, et al. Navigating parental hesitancy in public health: the case for RSV immunization in newborns. J Perinatol. 2025;[Epub ahead of print].

[91] Schaerlaekens S, Jacobs L, Stobbelaar K, Cos P, Delputte P. All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design? Vaccines (Basel). 2024; 12: 97.

[92] Regan AK. The safety of maternal immunization. Hum Vaccin Immunother. 2016; 12: 3132-6.

[93] Etti M, Calvert A, Galiza E, Lim S, Khalil A, Le Doare K, et al. Maternal vaccination: a review of current evidence and recommendations. Am J Obstet Gynecol. 2022; 226: 459-74.

[94] Santilli V, Sgrulletti M, Costagliola G, Beni A, Mastrototaro MF, Montin D, et al. ; Italian Society of Pediatric Allergy and Immunology (SIAIP) Vaccine Committee. Maternal Immunization: Current Evidence, Progress, and Challenges. Vaccines (Basel). 2025; 13: 450.

[95] Harris E. Safety Concerns Put a Stop to Maternal RSV Vaccine Study. JAMA. 2024; 331: 1439.

[96] Boytchev H. Maternal RSV vaccine: Further analysis is urged on preterm births. BMJ. 2023; 381: 1021.

[97] Alami A, Pérez-Lloret S, Mattison DR. Safety surveillance of respiratory syncytial virus (RSV) vaccine among pregnant individuals: a real-world pharmacovigilance study using the Vaccine Adverse Event Reporting System. BMJ Open. 2025; 15: e087850.

[98] MacDonald NE ; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015; 33: 4161-4.

[99] Larson HJ, Gakidou E, Murray CJL. The Vaccine-Hesitant Moment. N Engl J Med. 2022; 387: 58-65.

[100] Sallam M. COVID-19 Vaccine Hesitancy Worldwide: A Concise Systematic Review of Vaccine Acceptance Rates. Vaccines (Basel). 2021; 9: 160.

[101] Herdea V, Tarciuc P, Ghionaru R, Lupusoru M, Tataranu E, Chirila S, et al. Vaccine Hesitancy Phenomenon Evolution during Pregnancy over High-Risk Epidemiological Periods-“Repetitio Est Mater Studiorum”. Vaccines (Basel). 2023; 11: 1207.

[102] Karafillakis E, Francis MR, Paterson P, Larson HJ. Trust, emotions and risks: Pregnant women’s perceptions, confidence and decision-making practices around maternal vaccination in France. Vaccine. 2021; 39: 4117-25.

[103] Danchin MH, Costa-Pinto J, Attwell K, Willaby H, Wiley K, Hoq M, et al. Vaccine decision-making begins in pregnancy: Correlation between vaccine concerns, intentions and maternal vaccination with subsequent childhood vaccine uptake. Vaccine. 2018; 36: 6473-9.

[104] Surti MS, Amarbayan MM, McNeil DA, Hayden KA, Donald M, Patey AM, et al. Resources available for parent-provider vaccine communication in pregnancy in Canada: a scoping review. BMJ Open. 2023; 13: e072473.

[105] Sallam M. The fragility of public health in the face of controversial leadership. BMJ Glob Health. 2025; 10: e018536.

[106] Sallam M, Al-Baidhani S, Sallam M. Addressing Vaccine Hesitancy in the Age of Measles Resurgence: A Mini-Review. Vaccines Vaccin Open Access. 2025; 10: 000178.

[107] Singh P, Fesshaye B, Lee C, Njogu RN, Karron RA, Limaye RJ. Maternal Immunization Decision-Making Among Pregnant and Lactating People in Kenya: A Qualitative Exploration of Peer Influences on Vaccine Decision-Making for a Future RSV Vaccine. Matern Child Health J. 2024; 28: 1822-32.

[108] Comparcini D, Tomietto M, Pastore F, Nichol B, Miniscalco D, Flacco ME, et al. Factors Influencing COVID-19 Vaccine Hesitancy in Pregnant and Breastfeeding/Puerperium Women: A Cross-Sectional Study. Vaccines (Basel). 2024; 12: 772.

[109] Olde Loohuis KM, de Kok BC, Bruner W, Jonker A, Salia E, Tunçalp Ö, et al. Strategies to improve interpersonal communication along the continuum of maternal and newborn care: A scoping review and narrative synthesis. PLOS Glob Public Health. 2023; 3: e0002449.

[110] Verweij M, Lambach P, Ortiz JR, Reis A. Maternal immunisation: ethical issues. Lancet Infect Dis. 2016; 16: e310-4.

[111] Razai MS, Mansour R, Goldsmith L, Freeman S, Mason-Apps C, Ravindran P, et al. Interventions to increase vaccination against COVID-19, influenza and pertussis during pregnancy: a systematic review and meta-analysis. J Travel Med. 2023; 30: taad138.

[112] Properzi S, Carestia R, Birettoni V, Calesso V, Marinelli B, Scapicchi E, et al. Vaccination of pregnant women: an overview of European policies and strategies to promote it. Front Public Health. 2024; 12: 1455318.

[113] Gagnon D, Gubany C, Ouakki M, Malo B, Paquette M, Brousseau N, et al. Factors influencing acceptance of RSV immunization for newborns among pregnant individuals: A mixed-methods study. Vaccine. 2025; 55: 127062.

[114] Wiwanitkit S, Wiwanitkit V. RSV awareness, risk perception, causes, and terms: Comment. Hum Vaccin Immunother. 2023; 19: 2277086.

[115] Limaye RJ, Singh P, Fesshaye B, Karron RA. Lessons learned from COVID-19 vaccine acceptance among pregnant and lactating women from two districts in Kenya to inform demand generation efforts for future maternal RSV vaccines. BMC Pregnancy Childbirth. 2024; 24: 221.

[116] Williams TC, Marlow R, Cunningham S, Drysdale SB, Groves H, Iskander D, et al. ; PERUKI & BronchStart Collaboration. Maternal views on RSV vaccination during the first season of implementation in England and Scotland. Lancet Infect Dis. 2025; 25: e135-6.

[117] Razzaghi H, Garacci E, Kahn KE, Lindley MC, Jones JM, Stokley S, et al. Maternal Respiratory Syncytial Virus Vaccination and Receipt of Respiratory Syncytial Virus Antibody (Nirsevimab) by Infants Aged <8 Months - United States, April 2024. MMWR Morb Mortal Wkly Rep. 2024; 73: 837-43.

[118] World Health Organization. WHO Global Market Study on RSV Immunization Products [Internet]. WHO; c2025 [cited 2025 Jul 12]. Available from: https://www.who.int/publications/m/item/who-global-market-study-on-rsv-immunization-products

[119] Baral R, Otiang E, Odiyo J, Nyawanda BO, Nyiro JU, Munywoki P, et al. Cost of delivering childhood RSV prevention interventions to the health system in Kenya: a prospective analysis. BMJ Open. 2024; 14: e084207.

[120] Fleming-Dutra KE, Jones JM, Roper LE, Prill MM, Ortega-Sanchez IR, Moulia DL, et al. Use of the Pfizer Respiratory Syncytial Virus Vaccine During Pregnancy for the Prevention of Respiratory Syncytial Virus-Associated Lower Respiratory Tract Disease in Infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023; 72: 1115-22.

[121] Manca TA, Top KA, Graham JE. COVID-19 vaccination in pregnancy: How discrepant public health discourses shape responsibility for fetal health. SSM Qual Res Health. 2023; 3: 100265.

[122] Wu PP, Ding FR. Administration of Nirsevimab for RSV Prophylaxis in Infants: A Comprehensive Review. Vaccines (Basel). 2025; 13: 470.

[123] Plock N, Sachs JR, Zang X, Lommerse J, Vora KA, Lee AW, et al. Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease. Commun Med (Lond). 2025; 5: 119.

[124] Rumfelt KE, Pike M, Stolarczuk JE, Lekander A, Lauring AS, Eckert LO, et al. Maternal-Infant Respiratory Syncytial Virus and Influenza A Virus Antibody Transfer in Preterm and Full-term Infants. Open Forum Infect Dis. 2024; 12: ofae723.

[125] Parkinson J, Chu H. Understanding the Nuances of the RSV Maternal Vaccine and Monoclonal Antibody for the Pediatric Population [Internet]. [Cited 2025 Jul 11]. Available from: https://www.contagionlive.com/view/understanding-the-nuances-of-the-rsv-maternal-vaccine-and-monoclonal-antibody-for-the-pediatric-population

[126] Hansen CL, Lee L, Bents SJ, Perofsky AC, Sun K, Starita LM, et al. Scenario Projections of Respiratory Syncytial Virus Hospitalizations Averted Due to New Immunizations. JAMA Netw Open. 2025; 8: e2514622.